Apolipoprotein E (apo E) is a major plasma apolipoprotein that is associated with very low density lipoprotein (VLDL) and with subfractions of high density lipoprotein (HDL). Apo E plays an important role in cholesterol metabolism by virtue of its interaction with cell surface receptors. This activity appears to be crucial for the rapid removal by the liver of apo E-containing remnant particles derived from lipoprotein metabolism in peripheral tissues. This process of reverse cholesterol transport which moves cholesterol from peripheral tissues to the liver is important in preventing the accumulation of cholesterol and cholesterol esters in the arterial wall as occurs in atherosclerosis. In contrast to most apolipoproteins which are synthesized primarily at the major sites of lipoprotein production in the liver and small intestine, apo E is synthesized at high rates in a variety of peripheral tissues including adrenal gland, kidney, skin, and brain. Apo E synthesis shows complex patterns of tissue-specific regulation which are influenced by cellular cholesterol metabolism, an array of regulatory molecules, and the developmental stage of the cell. Two of the projects in this proposal are focused on the regulation of apo E expression. In the first, experiments are proposed to determine how apo E synthesis is altered in response to changes in cholesterol metabolism in rat adrenal gland. These experiments include measurements of apo E synthesis, apo E mRNA, and apo E gene transcription to establish the level of regulation. Adrenal cells responding to altered cholesterol metabolism will be identified by immunocytochemical and in situ hybridization procedures. Primary cultures of adrenal cells will be used to explore the mechanisms through which apo E expression is altered. A second project will determine the DNA elements in the apo E. gene that are required for metabolic and developmental regulation. These studies will use transient transfection assays and stable transformation protocols to introduce test genes carrying apo E regulatory sequences into cultured cells. Subsequent alterations of cellular cholesterol metabolism or the developmental stage of the cell will test which apo E DNA sequences are required to respond to these stimuli. These experiments will also specifically test the role of the 5' non-coding region of apo E mRNA in the regulation of apo E synthesis. A third project will examine the influence of dietary fat and cholesterol on the expression of genes coding for the major plasma apolipoproteins (apo AI, apo AII, apo B100, apo B48, apo E) and the low density lipoprotein (LDL) receptor. These studies will involve the determination of steady-state mRNA concentrations for each of these proteins in the livers and small intestines of animals fed diets containing different amounts of cholesterol in combination with saturated fat or diets containing fats which differ in the degree of saturation. These studies ask about the mechanisms through which dietary fat and cholesterol alter the concentrations of plasma LDL and HDL. The plasma concentrations of these lipoproteins are important factors in the development of atherosclerotic heart disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL032868-08
Application #
3344401
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1984-06-01
Project End
1994-05-31
Budget Start
1991-06-01
Budget End
1992-05-31
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
State University New York Stony Brook
Department
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Ma, Yanqing; Malbon, Craig C; Williams, David L et al. (2008) Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E. PLoS One 3:e2503
Zhao, Yue; Thorngate, Fayanne E; Weisgraber, Karl H et al. (2005) Apolipoprotein E is the major physiological activator of lecithin-cholesterol acyltransferase (LCAT) on apolipoprotein B lipoproteins. Biochemistry 44:1013-25
Mann, Karen M; Thorngate, Fayanne E; Katoh-Fukui, Yuko et al. (2004) Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet 13:1959-68
Wientgen, Hilke; Thorngate, Fayanne E; Omerhodzic, Sabina et al. (2004) Subphysiologic apolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 24:1460-5
Thorngate, Fayanne E; Yancey, Patricia G; Kellner-Weibel, Ginny et al. (2003) Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression. J Lipid Res 44:2331-8
Temel, Ryan E; Parks, John S; Williams, David L (2003) Enhancement of scavenger receptor class B type I-mediated selective cholesteryl ester uptake from apoA-I(-/-) high density lipoprotein (HDL) by apolipoprotein A-I requires HDL reorganization by lecithin cholesterol acyltransferase. J Biol Chem 278:4792-9
Thorngate, Fayanne E; Strockbine, Penelope A; Erickson, Sandra K et al. (2002) Altered adrenal gland cholesterol metabolism in the apoE-deficient mouse. J Lipid Res 43:1920-6
Swarnakar, S; Beers, J; Strickland, D K et al. (2001) The apolipoprotein E-dependent low density lipoprotein cholesteryl ester selective uptake pathway in murine adrenocortical cells involves chondroitin sulfate proteoglycans and an alpha 2-macroglobulin receptor. J Biol Chem 276:21121-8
DeMattos, R B; Rudel, L L; Williams, D L (2001) Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res 42:976-87
Thorngate, F E; Rudel, L L; Walzem, R L et al. (2000) Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 20:1939-45

Showing the most recent 10 out of 55 publications